Florian Moik

[Simon Kraler @KralerSimon]

Check out our #ESCCongress 2024 simultaneous #CardioOncology publication on a novel risk score for MACE in cancer patients - now online @JTHjournal https://t.co/sFy0vHk24I

Lucky me to have such a great team!

Many thanks to @liberale_luca @Cihan_Ay_MD @FlorianMoik @TomLuscher

[JTH @JTHjournal]

Join #ESCardio oral session NOW: ‘Risk prediction and treatment options in cardio-oncology’

▶️Simultaneous publication with @escardio congress: @KralerSimon & @FlorianMoik report on a novel risk score to predict cardiovascular risk in #cancer patients

Look out for the paper, coming soon!! #Cardiotwitter

[Luca Liberale @liberale_luca]

Join us right now at Science Box 4 #ESCCongress as @KralerSimon present our results on CV risk stratification in patients with cancer. A great collaboration @UniGenova @cmc_uzh @MedUni_Wien

@FlorianMoik @CarboneF82 @DavideRamoni @Cihan_Ay_MD @wenzl_florian @TomLuscher

[Jakob M. Riedl @JakobMRiedl]

Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study https://t.co/OgdOhgb0xx

Happy to share our recently published article!

[Center for Molecular Cardiology @cmc_uzh]

Now up @JTHjournal

GDF-15 improves CV risk assessment, but predictive utility in cancer patients remained unknown

👉 https://t.co/pLc5CkyEdt

Thank you @Cihan_Ay_MD @FlorianMoik for the fantastic collaboration
@KralerSimon @TomLuscher @UZH_en @isth @MedUni_Wien @ELS_Cardiology

[JTH @JTHjournal]

GDF-15, thrombosis & #cancer: New insights show GDF-15, a #cardiovascular risk biomarker, is strongly linked to all-cause mortality in cancer patients, yet fails to improve #VTE prediction models. Learn more: #Thrombosis #CancerResearch
https://t.co/zju1syUX8f

[MedUni Wien @MedUni_Wien]

Der vfwf vergab im Rahmen der Regine Kapeller-Adler Lecture Preise für die besten #Dissertationen und #Habilitationen an der #MedUniWien für 2022 und 2023. Wir gratulieren den Preisträger:innen! ➡️ https://t.co/fIAT89mzqY

@loizoujoanna, @florianmoik, @mdnitsche

[Nicolas Gendron @GendronNico]

🆎🅾️ blood group type and risk of venous thromboembolism in patients with cancer
Non-🅾️ blood type is a time-dependent predictor of cancer-associated VTE.
https://t.co/AZgWukqvm7
👏👏@Cihan_Ay_MD @FlorianMoik @IngridPabinger

[Dino Mehic @dino_mehic]

Two impressive talks by @FlorianMoik (@MedUni_Wien & @MedUniGraz) on the better understanding of #CAT cancer associated thrombosis #ASH2022

[Cihan Ay @Cihan_Ay_MD]

The interrelation between cancer and haemostatic system is multifaceted. @FlorianMoik presents an overview at #ASH22 in the Friday special symposium on cancer and malignancy. @ASH_hematology

[JTH @JTHjournal]

#Haemostasis & #Cancer @Cihan_Ay_MD, @FlorianMoik discuss potential biomarkers that might be used to contribute to #risk-stratified, #personalized cancer treatment @MedUni Wien https://t.co/Q7Jrs7NHo5

[Cihan Ay @Cihan_Ay_MD]

Comprehensive analysis of venous and arterial thrombosis in patients with cancer treated with targeted anti-cancer therapies. Collaborative work presented by @FlorianMoik at #ISTH2021. Causality or reflection of underlying tumor-type specific risk? @dceaarhus @ToftSorensen @isth

[Alok Khorana, MD @aakonc]

New data re VTE/ATE rates with newer cancer therapies #ISTH2021 by Moik et al @Cihan_Ay_MD

[Jakob M. Riedl @JakobMRiedl]

Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line... https://t.co/PLIFMeXSbX

Happy to share our study which demonstrates similar effectiveness for Gemcitabine/nab-Paclitaxel and FOLFIRINOX for palliative first line treatment in advanced pancreatic cancer

[Oncology Tube @oncologytube]

Incidence, Risk Factors, And Outcomes Of Venous And Arterial Thromboembolism In Immune Checkpoint Inhibitor Therapy Dr med Florian Moik @FlorianMoik @Cihan_Ay_MD @MedUni_Wien @CCC_Vienna #ImmuneCheckPointInhibitors #Cancer #Research

https://t.co/jzKIvhOCX9...

[Cihan Ay @Cihan_Ay_MD]

Thrombosis is common in cancer pts treated with immune checkpoint inhibitors. Was not reported in registration trials. Just reflecting baseline risk of thrombosis in cancers treated with these new anti-cancer treatments or causal relation?
@BloodJournal https://t.co/HEw3KjKa7Q

[Florian Moik @FlorianMoik]

Highly honoured and thankful to be awarded with the GTH Early Career Research Grant 2021. Special thanks to my supervisor @Cihan_Ay_MD
#GTH2021

[Annual Meeting GTH @AnnualGth]

At the @AnnualGth #GTH2021 Opening,
Dr med Florian MOIK @FlorianMoik, from the University of Vienna @MedUni_Wien, received one of three GTH Early Research Career Grant #researchgrant #hemostasis
#Congratulations!

Join us at https://t.co/rR9UvgX4Ek

[RPTH @RPTHjournal]

#RPTH Top 10 Altmetric Scores of 2020: No. 10 – @FlorianMoik @cczielinski & @Cihan_Ay_MD performed a meta-analysis of #RCTs in patients with cancer-associated #VTE to compare outcomes of #DOAC to #LMWH treatment. https://t.co/wib5CYhKlH

[Cihan Ay @Cihan_Ay_MD]

@FlorianMoik presents data of his MDPhD project on the role of biomarkers indicating activation of haemostasis/fibrinolysis for prediction of prognosis & oncological outcomes (PFS, chemo response) in pts with pancreatic cancer. Hypercoagulability ➡️bad prognostic factor. #ASH20

[Dino Mehic @dino_mehic]

Great talk by my colleague @FlorianMoik on the association of hemostatic biomarkers with mortality in pancreatic cancer #ASH20